"Do Not Use Weight-Loss Injections Without Caution": MFDS Issues Warning

Amid the rising use of GLP-1 (glucagon-like peptide-1) receptor agonist obesity treatments such as Wegovy, the Ministry of Food and Drug Safety (MFDS) has urged the public to use these medications with caution, strictly following prescribed guidelines and approved usage.
In a press release issued yesterday (July 8), the MFDS stated, "GLP-1 obesity treatments are prescription drugs intended for adult patients with a body mass index (BMI) of 30 kg/㎡ or higher, or for overweight adults with a BMI between 27 kg/㎡ and 30 kg/㎡ who have at least one weight-related comorbidity, such as hypertension."
The ministry particularly emphasized that for adolescents, "as they are in a stage where growth is not yet complete, caution is required regarding potential nutritional deficiencies and weight loss."
The MFDS requested that the public refrain from distributing these drugs through private sales or overseas direct purchases, noting that they are prescription medications that must be used under a doctor's prescription and a pharmacist's guidance.
The ministry added, "Products purchased through overseas direct channels carry risks, such as being counterfeit or substandard, as their manufacturing and distribution processes cannot be verified. Furthermore, it is difficult to receive legal protection, such as recalls or compensation, if harm occurs during use."
The MFDS plans to work with local governments to inspect medical institutions and pharmacies for any off-label promotion or exaggerated advertising of obesity treatments.
※ Please note: This article was translated by AI and may contain errors.